HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100CompaniesDeal TrackerResearch
Biotech

Fresenius Kabi

1
Articles
Deal Party
Top Role
Apr 11, 2026
First Mention
Apr 11, 2026
Last Mention
1.55
Relevance Score

Coverage Timeline

April 2026
Biosimilars Beyond Humira: New Pressures and Unwritten Rules for Stelara, Keytruda, and Eylea in 2026 Pipeline Deal Party
Apr 11, 2026
Fresenius Kabi, Sandoz, and Amgen are all chasing pembrolizumab biosimilars.
Related Companies
Alvotech
1 shared
Celltrion
1 shared
Samsung Bioepis
1 shared
Sandoz International GmbH
1 shared
Regeneron Pharmaceuticals, Inc.
1 shared
Johnson & Johnson
1 shared
Amgen Inc.
1 shared
Merck & Co., Inc.
1 shared